Statin Benefits Those With High hsCRP, Intermediate CVD Risk

Rosuvastatin reduces cardiac events in patients at intermediate risk even if cholesterol is normal

WEDNESDAY, Aug. 25 (HealthDay News) -- Rosuvastatin may reduce the risk of major adverse cardiovascular events in men and women with normal cholesterol but elevated high-sensitivity C-reactive protein (hsCRP) levels who are at intermediate risk for cardiovascular disease (CVD), according to research published online Aug. 24 in Circulation: Cardiovascular Quality and Outcomes.

Paul M. Ridker, M.D., of Harvard Medical School in Boston, and colleagues performed a new analysis of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin, which compared rosuvastatin 20 mg against placebo in 17,802 primary prevention patients with low-density lipoprotein cholesterol below 130 mg/dL and hsCRP of at least 2 mg/L. Rosuvastatin was found to result in a 44 percent reduction in first vascular events in these patients compared with placebo.

In the new analysis, the researchers found that rosuvastatin was associated with a 45 percent reduction in the relative risk of CVD for those whose estimated 10-year Framingham risk ranged from 5 to 10 percent and a 49 percent reduction for people estimated to have a 10-year CVD risk of 11 to 20 percent.

"Clinically, our data provide consistent support for the position taken by the American Heart Association and Centers for Disease Control that the use of hsCRP probably is best among those at 5 to 10 percent and 10 to 20 percent 10-year risk, groups in which controversy is present regarding the utility and effectiveness of statin therapy," the authors write.

The trial was supported by AstraZeneca. Several authors disclosed financial relationships with medical device and/or pharmaceutical companies, including AstraZeneca, and one author is a co-inventor on patents related to use of inflammatory biomarkers in CVD that have been licensed to Seimens and AstraZeneca.

Full Text (subscription or payment may be required)

Physician's Briefing